Skip to main content
. 2021 Aug 7;65(18):2100222. doi: 10.1002/mnfr.202100222

Figure 2.

Figure 2

Study timeline and bodyweight development in the pectins and TLR2 treated doxorubicin treated mice. A) Mice received pectins or water via oral administration for a period of 9 days. On day 7, TLR2 blocking antibody and doxorubicin were intraperitoneally injected and mucositis was induced. Mice were sacrificed on day 9. B) Bodyweight was measured of control (n = 7), doxorubicin (dox; n = 7), doxorubicin + TLR2 blocking antibody (n = 7), doxorubicin + DM18 pectin (low DB; n = 7), doxorubicin + DM19 (high DB; n = 8), doxorubicin + DM49 (low DB; n = 8), and doxorubicin + DM43 (high DB; n = 8) treated mice to follow changes after pectin and doxorubicin treatment. C) Final weight loss compared to day 0 was also determined. Data is represented as mean ± SD. a–d indicate statistical differences (p < 0.05) between doxorubicin and other experimental groups as quantified with one‐way ANOVA test and Tukey's post‐hoc test.